| [1] |
H udson E, Lester JF, Attanoos RL, et al. Successful treatment of bronchorrhea with octreotide in a patient with adenocarcinoma of the lung. J Pain Symptom Manage, 2006,32(3):200-202.
|
| [2] |
Verwijnen SM, Sillevis Smith PA, Hoeben RC, et al. Molecular imaging and treatment of malignant gliomas following adenoviral transfer of tile herpes sinlplex virus-thymidine kinase gene and the somatostatin receptor subtype 2 gene. Cancer Biother Radiopharm, 2004, 19(1):111-120.
|
| [3] |
Mussig K, Petersenn S, Wehrmann M, et al. Somatostatin receptor expression in a parathyroid hormone-related peptlde-secreting pancreatic neuroendocrine turnout causing severe hypercalcaemia. Eur J Gastroenterol Hepatol, 2007,19(8):719-723.
|
| [4] |
Bangard M, Behe M, Guhlke S, et al. Detection of somatostatin receptor-positive tumours using the 99mTc-tricine-HYNIC-D-Phe1-Thy3-octreotide:first results in patients and comparison with 111In-DTPA-D-Phel-octreotide. Eur J Nucl Med, 2000, 27(6):628-637.
|
| [5] |
Sehmitt A, Bernhardt P, Nilsson O, et ah Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model. Cancer Biother Radiopharm, 2005, 20(2):231-236.
|
| [6] |
Bushnell D, Menda Y, Madsen M, et al. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher] treatment. Cancer Biother Radiopharm, 2004, 19(1):35-41.
|